The Federal Trade Commission endorsed the US Patent and Trademark Office’s proposal to expand the requirement for when companies must file settlement agreements.
The agency supports closing a loophole that presently allows parties to circumvent disclosure requirements if they settle before an administrative tribunal decides whether to review a patent validity challenge, according to the Tuesday comment. Extending disclosure obligations to a broader set of settlement agreements would enhance the FTC’s ability to identify and investigate potentially unlawful settlements in the pharmaceutical context and more broadly, the agency said.
The PTO published a highly-anticipated rulemaking on April 19 to ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.